New Australian patent approval for Episurf Medical

The Australian patent office IP Australia has issued a Notice of acceptance for another patent for Episurf Medical (NASDAQ: EPIS B) in Australia. The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair” covers Episurf Medical’s medical image segmentation process used for joint structure visualisation.

 "This patent covers important details of the segmentation process Episurf Medical uses for 3D visualisation of joints, which is a central part of our technology platform”, comments Katarina Flodström, CRO & Head of IP, Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.35 CEST on 29 August 2018.

Tags: